A fully human antibody that inhibits the integrin avb6 reduces tumour growth and modulates key biomarkers
Session type: Poster / e-Poster / Silent Theatre session
1AstraZeneca, Cheshire, UK, 2Amgen, Vancouver, Canada
Increased expression of the integrin avb6 occurs in a number of human cancers including lung, colorectal, breast, head and neck, and prostate cancer. In normal tissues avb6 plays a key role in modulating the activation of latent TGFb, by binding the TGF-b latency associated peptide LAP through the high affinity binding site RGDLxxL. In addition avb6 also binds the extracellular matrix component fibronectin. By binding both latent TGF-b and fibronectin avb6 has the potential to influence tumour growth by activating both TGF-b or classical integrin mediated signalling pathways.